Country Belgium
Region Région wallonne
Investor Capricorn Venture Partners, SRIW, Vesalius

Starting life as a spin-out from the University of Brussels, drug discovery business Ogeda raised its last round of funding from a group of venture capital investors, including Capricorn Venture Partners, in 2015. With support from its investors, the company develope fezolinetant, which has potential to treat a number of women’s disorders: hot flashes, uterine fibroids, polycystic ovarian syndrome without the use of hormones.

With phase II studies completed - a major milestone in the company’s development - the business was acquired by Japanese pharmaceutical company Astellas in 2017. The sale value of €500m upfront, with a further €300m on completion of certain milestones, generates a substantial 10x return for Capricorn’s investors. 

Our financial backers provided support required to achieve proof-of-concept in clinical phase IIa for the first non-hormonal treatment of hot flashes.

Jean Combalbert CEO, Ogeda

What did the business need?

  • Strategic direction
  • Partnerships with pharma companies
  • Means to develop internal drug pipeline

How did private equity backing create lasting value?

  • Provided strategic advice to create commercially viable and attractive business
  • Refocused business from chemistry service provider to drug development company
  • Funded the clinical development of fezolinetant from concept to phase II
  • Assembled experienced management team and board of directors to drive Ogeda’s development

What outcomes did private equity investment achieve?

  • Created an attractive, valuable drug development company
  • Supported the development of a new, potentially revolutionary treatment for women’s health issues without the use of hormones
  • Created a business employing 40 people
  • Placed Ogeda on long-term, sustainable growth path through sale to Astellas
  • Generated substantial returns to investors


employees in 2017


return generated for investors

Case study image

For more info

We've updated our privacy policy in response to the General Data Protection Regulation (GDPR) effective as of 25 May 2018. You can review our updated privacy policy and if you have any comments please contact us.

I have reviewed the updated Privacy Policy